Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 161

1.

Risk factors for histological progression of nonalcoholic steatohepatitis analyzed from repeated biopsy cases.

Daijo K, Nakahara T, Inagaki Y, Nanba M, Nishida Y, Uchikawa S, Kodama K, Oya K, Morio K, Fujino H, Ono A, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Hayes CN, Imamura M, Aikata H, Ochi H, Chayama K.

J Gastroenterol Hepatol. 2020 Jan 2. doi: 10.1111/jgh.14968. [Epub ahead of print]

PMID:
31896166
2.

Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection.

Ohya K, Kawaoka T, Imamura M, Morio K, Nakahara T, Murakami E, Yamauchi M, Hiramatsu A, Tsuge M, Aikata H, Chayama K.

Intern Med. 2019 Dec 6. doi: 10.2169/internalmedicine.3824-19. [Epub ahead of print]

3.

Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.

Fujino H, Tanaka M, Imamura M, Morio K, Ono A, Nakahara T, Murakami E, Kawaoka T, Takahashi S, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Chayama K.

BMC Gastroenterol. 2019 Oct 24;19(1):169. doi: 10.1186/s12876-019-1092-z.

4.

Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.

Saito Y, Imamura M, Uchida T, Osawa M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Serikawa M, Aikata H, Abe-Chayama H, Hayes CN, Chayama K.

J Med Virol. 2020 Feb;92(2):210-218. doi: 10.1002/jmv.25602. Epub 2019 Oct 16.

PMID:
31584207
5.

Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.

Namba M, Hiramatsu A, Aikata H, Kodama K, Uchikawa S, Ohya K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Tsuge M, Imamura M, Chayama K.

J Gastroenterol. 2019 Sep 4. doi: 10.1007/s00535-019-01623-4. [Epub ahead of print]

PMID:
31485782
6.

Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.

Ohya K, Imamura M, Osawa M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Hiramatsu A, Tsuge M, Aikata H, Hayes CN, Chayama K.

Clin J Gastroenterol. 2019 Aug 28. doi: 10.1007/s12328-019-01039-w. [Epub ahead of print]

PMID:
31463795
7.

Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy.

Ohya K, Kawaoka T, Namba M, Uchikawa S, Kodama K, Morio K, Nakahara T, Murakami E, Hiramatsu A, Tsuge M, Yamauchi M, Imamura M, Chayama K, Aikata H.

Sci Rep. 2019 Aug 20;9(1):12101. doi: 10.1038/s41598-019-48045-z.

8.

Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.

Osawa M, Uchida T, Imamura M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Ishida Y, Tateno C, Miyayama Y, Hijikata M, Chayama K.

J Gen Virol. 2019 Jul;100(7):1123-1131. doi: 10.1099/jgv.0.001268. Epub 2019 Jun 14.

PMID:
31199224
9.

Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP.

Makokha GN, Abe-Chayama H, Chowdhury S, Hayes CN, Tsuge M, Yoshima T, Ishida Y, Zhang Y, Uchida T, Tateno C, Akiyama R, Chayama K.

Sci Rep. 2019 Jun 11;9(1):8462. doi: 10.1038/s41598-019-44934-5.

10.

Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection.

Tsuge M, Uchida T, Walsh K, Ishida Y, Tateno C, Kumar U, Glenn JS, Koh C, Heller T, Uprichard SL, Dahari H, Chayama K.

Viruses. 2019 Mar 15;11(3). pii: E263. doi: 10.3390/v11030263.

11.

Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis.

Hiramatsu A, Aikata H, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Honda F, Inagaki Y, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Imamura M, Tanaka J, Chayama K.

Hepatol Commun. 2019 Jan 22;3(3):348-355. doi: 10.1002/hep4.1309. eCollection 2019 Mar.

12.

Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice.

Tsushima K, Tsuge M, Hiraga N, Uchida T, Murakami E, Makokha GN, Kurihara M, Nomura M, Hiyama Y, Fujino H, Ono A, Nakahara T, Yamauchi M, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Aikata H, Hayes CN, Chayama K.

J Gastroenterol. 2019 Jul;54(7):650-659. doi: 10.1007/s00535-019-01558-w. Epub 2019 Feb 21.

PMID:
30790056
13.

Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.

Namba M, Kawaoka T, Aikata H, Kodama K, Uchikawa S, Ohya K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M, Baba Y, Awai K, Chayama K.

Clin J Gastroenterol. 2019 Aug;12(4):341-346. doi: 10.1007/s12328-019-00938-2. Epub 2019 Jan 31.

PMID:
30706429
14.

Correction: Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.

Tatsukawa Y, Tsuge M, Kawakami Y, Hiyama Y, Murakami E, Kurihara M, Nomura M, Tsushima K, Uchida T, Nakahara T, Miki D, Kawaoka T, Abe-Chayama H, Imamura M, Aikata H, Ochi H, Hayes CN, Kawakami H, Chayama K.

Antivir Ther. 2019;23(8):709. doi: 10.3851/IMP3289. No abstract available.

PMID:
30632982
15.

Early experience of seven hepatocellular carcinoma cases treated with regorafenib.

Uchikawa S, Kawaoka T, Aikata H, Kodama K, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Hiramatsu A, Tsuge M, Imamura M, Kawakami Y, Chayama K.

Clin Case Rep. 2018 Oct 11;6(11):2217-2223. doi: 10.1002/ccr3.1791. eCollection 2018 Nov.

16.

The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.

Nagaoki Y, Imamura M, Nishida Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Fujino H, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Miki D, Hiyama Y, Ochi H, Chayama K, Aikata H.

J Med Virol. 2019 Apr;91(4):650-658. doi: 10.1002/jmv.25352. Epub 2018 Nov 19.

PMID:
30381831
17.

Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.

Osawa M, Imamura M, Teraoka Y, Uchida T, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Chayama K; Hiroshima Liver Study Group.

J Gastroenterol. 2019 Mar;54(3):291-296. doi: 10.1007/s00535-018-1520-9. Epub 2018 Oct 17.

PMID:
30334096
18.

Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes.

Tsuge M, Hiraga N, Zhang Y, Yamashita M, Sato O, Oka N, Shiraishi K, Izaki Y, Makokha GN, Uchida T, Kurihara M, Nomura M, Tsushima K, Nakahara T, Murakami E, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Kawakami Y, Aikata H, Ochi H, Hayes CN, Fujita T, Chayama K.

Virology. 2018 Dec;525:48-61. doi: 10.1016/j.virol.2018.08.020. Epub 2018 Sep 18.

19.

Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma.

Kawaoka T, Aikata H, Kobayashi T, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Inagaki Y, Honda F, Hatooka M, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Baba Y, Awai K, Chayama K.

Hepatol Res. 2018 Dec;48(13):1118-1130. doi: 10.1111/hepr.13232. Epub 2018 Aug 23.

PMID:
30030881
20.

Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.

Morio K, Imamura M, Kawakami Y, Nakamura Y, Hatooka M, Morio R, Fujino H, Nakahara T, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Miki D, Ochi H, Katamura Y, Arataki K, Moriya T, Ito H, Tsuji K, Kohno H, Waki K, Tamura T, Nakamura T, Chayama K; Hiroshima Liver Study Group.

J Med Virol. 2018 Dec;90(12):1834-1840. doi: 10.1002/jmv.25267. Epub 2018 Aug 13.

PMID:
30016555

Supplemental Content

Loading ...
Support Center